Optimal scheduling of post-therapeutic follow-up of patients treated for cancer for early detection of relapses

Abstract

Post-therapeutic surveillance is one important component of cancer care. However, there still is no evidence-based strategies to schedule patients’ follow-up examinations. Our approach is based on the modeling of the probability of the onset of relapse at an early asymptotic or preclinical stage and its transition to a clinical stage. For that we consider a multistate homogeneous Markov model, which includes the natural history of relapse. The model also handles separately the different types of possible relapses. The optimal schedule is provided by the calendar visit that maximizes a utility function. The methodology has been applied to laryngeal cancer. The different follow-up strategies revealed to be more efficient than those proposed by different scientific societies.

Keywords

post-therapeutic follow-up optimal scheduling cancer natural history multistate Markov model utility function

Get full access to this article

View all access options for this article.

References

Zelen

Feinleib

. On the theory of screening for chronic diseases. Biometrila 1969; 56: 601–614.

Day

Walter

. Simplified models of screening for chronic disease: estimation procedures from mass screening programmes. Biometrics 1984; 40: 1–1.

Stevenson

. Statistical models for cancer screening. Stat Methods Med Res 1995; 4: 18–32.

Van Oormarssen

Boer

Habbema

. Modelling issues in cancer screening. Stat Methods Med Res 1995; 4: 33–54.

Boer

Plevritis

Clarke

. Diversity of model approaches for breast cancer screening: a review of model assumptions by the Cancer Intervention and Surveillance Network (CISNET) Breast Cancer Groups. Stat Methods Med Res 2004; 13: 525–538.

Duffy

Sasieni

Olsen

et al.

Modelling the likely effect of the increase of the upper age limit from 70 to 73 for breast screening in the UK National Programme. Stat Methods Med Res 2010; 19: 547–555.

Kafadar

Prorok

. Computational methods in medical decision making: to screen or not to screen? Stat Med 2005; 24: 569–581.

Cowen

Chartrand

Weitzel

. A Markov model of the natural history of prostate cancer. J Clin Epidemiol 1994; 47: 3–21.

Duffy

Day

Tabar

et al.

Markov models of breast tumor progression: some age specific results. J Natl Cancer Inst Monogr 1997; 22: 93–97.

10.

Özekici

Pliska

. Optimal scheduling of inspections: a delayed Markov model with false positives and negatives. Oper Res 1991; 39: 261–273.

11.

Chen

Prevost

Duffy

. Evaluation of screening for nasopharyngeal carcinoma: trial design using Marcov chain models. Br J Cancer 1999; 79: 1894–1900.

12.

Uhry

Hédelin

Colonna

et al.

Multi-state Markov models in cancer screening evaluation: a brief review and case study. Stat Methods Med Res 2010; 19: 463–486.

13.

Somda SMA, Leconte E, Kramar A, et al. Determining the length of posttherapeutic follow-up for cancer patients using competing risks modeling. Med Decis Making 2014; 34: 168–179.

14.

Lee

Zelen

. Scheduling periodic examinations for the early detection of disease: application to breast cancer. J Am Stat Assoc 1998; 93: 1271–1281.

15.

Shen

Zelen

. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations. J Clin Oncol 2001; 19: 3490–3499.

16.

Shen

Parmigiani

. Optimization of breast cancer screening modalities 2003, Baltimore, MD: John Hopkins University, Department of Biostatistics Working Papershttp://biostats.bepress.com/jhubiostat/paper18 (accessed 20 February 2013).

17.

Shen

Zelen

. Robust modeling in screening studies: estimation of sensitivity of preclinical sojourn time distribution. Biostatistics 2005; 6: 604–614.

18.

Lee

Jeong

Kim

et al.

Scheduling mammography screening for early detection of breast cancer in Korean women. J Med Screen 2007; 14: 205–209.

19.

Draisma

van Rosmalen

. A note on the catch-up time method for estimating lead or sojourn time in prostate cancer screening. Stat Med 2013; 32: 3332–3341.

20.

Filleron

Dalenc

Kramar

. Personalised cancer follow-up: risk stratification, need assessment or both? Br J Cancer 2012; 106: 1579–1580.

21.

Fédération Nationale des Centres de Lutte Contre le Cancer. Référentiel et options thérapeutiques en cancérologie des VADS , 2008, http://www.oncolr.org/upload/Espace_patients/Referentielsregionaux/ONCO_LR_options_cancers_VADS_17_mars_2009.pdf (accessed 27 March 2013).

22.

NCCN. NCCN Guidelines for head and neck cancer care, 2010. , 2010, www.oralcancerfoundation.org/treatment/pdf/head-and-neck.pdf (accessed 27 March 2013).

23.

Haas

Hauser

Ganzer

. The dilemma of follow-up in head and neck cancer patients. Eur Arch Otorhinolaryngol 2001; 258: 177–183.

24.

Ataman

Barett

Davidson

et al.

Audit of effectiveness of routine follow-up clinics after radiotherapy for cancer: a report of the REACT Working Group of ESTRO. Radiother Oncol 2004; 73: 237–249.

25.

Filleron

Barett

Ataman

et al.

Planning post-therapeutic oncologic surveillance visits based on individual risks. Med Decis Making 2009; 29: 570–579.

26.

Wingo

Ries

LAG

Rosenberg

et al.

Cancer incidence and mortality, 1973–1995. Cancer 1998; 82: 1197–1207.

27.

Hofmann

Szedlak

Rittgen

et al.

Primary staging and follow-up in melanoma patients - monocenter evaluation of methods, costs and patients survival. Br J Cancer 2002; 87: 151–157.

28.

Francken

Shaw

Neil

et al.

Detection of first relapse in cutaneous melanoma patients: implication for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol 2007; 14: 1924–1933.

29.

Francken

Shaw

Thompson

. Detection of second primary cutaneous melanoma. Eur J Surg Oncol 2008; 34: 587–592.

30.

Wheeler

Stenning

Negus

et al.

Evidence to support a change in follow-up policy for patients with breast cancer: time to first relapse and hazard rate analysis. Clin Oncol 1999; 11: 169–173.

31.

Somda

SMA

Leconte

Kramar

et al.

Determining the length of posttherapeutic follow-up for cancer patients using competing risks modeling. Med Decis Making 2013. , 2013, http://mdm.sagepub.com/content/early/2013/06/21/0272989X13492015 (accessed 29 June 2013).

32.

Peronne

Musolino

Michiara

et al.

Early detection of recurrences in the follow-up of primary breast cancer in an asymptomatic or symptomatic phase. Tumori 2004; 90: 276–279.

33.

Zola

Fuso

Mazzola

et al.

Could follow-up different modalities play a role in asymptomatic cervical cancer relapses diagnosis? An italian multicenter retrospective analysis. Gynecol Oncol 2007; 107: S150–S154.

34.

Donnelly

Mack

Donaldson

. Follow-up of breast cancer: time for a new approach? Int J Clin Pract 2001; 55: 431–433.

35.

Tsao

Feldman

Fullerton

et al.

Early detection of asymptomatic pulmonary melanoma metastases by routinechest radiographs is not associated with improved survival. Arch Dermatol 2004; 140: 67–70.

36.

Nelder

Mead

. A simplex algorithm for function minimization. Comput J 1964; 7: 148–154.

37.

Ritoe

Krabbe

PFM

Kaanders

JHAM

et al.

Value of routine follow-up for patients cured of laryngeal carcinoma. Cancer 2004; 101: 1382–1389.

38.

Ritoe

De Vegt

Scheike

et al.

Effect of routine follow-up after treatment for laryngeal cancer on life expectancy and mortality. Results of a Markov model analysis. Am Cancer Soc 2007; 109: 239–247.

39.

Schwartz

Barker

Chansky

et al.

Postradiotherapy surveillance practice for head and neck squamous cell carcinoma - too much for too little?

Head Neck 2003; 25: 990–999.

40.

Lee

Zelen

. Modelling the early detection of breast cancer. Ann Oncol 2003; 14: 1199–1202.

41.

Pinsky

. An early- and late-stage convolution model for disease natural history. Biometrics 2004; 60: 191–198.

42.

Davidov

Zelen

. Designing cancer prevention trials: a stochastic model approach. Stat Med 2000; 19: 1983–1995.

43.

Draisma

Boer

Otto

et al.

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer. J Natl Cancer Inst 2003; 95: 868–878.

44.

Francken

Hoekstra

. Follow up of melanoma patients: the need for evidence-based protocols (editorial). Ann Surg Oncol 2009; 16: 804–805.

45.

Lee

Huang Zelen

. Early detection of disease and scheduling of screening examinations. Stat Methods Med Res 2004; 13: 443–456.

46.

Veestraeten

. An alternative approach to modelling relapse in cancer with an application to adenocarcinoma of the prostate. Math Biosci 2006; 199: 38–54.